Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Valion Bio (TIVC) Enterprise Value (2021 - 2026)

Valion Bio has reported Enterprise Value over the past 5 years, most recently at -$12.6 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 602.5% year-over-year to -$12.6 million; the TTM value through Dec 2025 reached -$12.6 million, down 602.5%, while the annual FY2025 figure was -$12.6 million, 602.5% down from the prior year.
  • Enterprise Value for Q4 2025 was -$12.6 million at Valion Bio, down from -$3.5 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$700000.0 in Q1 2025 and troughed at -$12.8 million in Q1 2021.
  • A 5-year average of -$5.4 million and a median of -$3.6 million in 2022 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: surged 76.01% in 2023 and later crashed 602.5% in 2025.
  • Year by year, Enterprise Value stood at -$12.8 million in 2021, then surged by 72.51% to -$3.5 million in 2022, then rose by 7.79% to -$3.2 million in 2023, then skyrocketed by 44.5% to -$1.8 million in 2024, then crashed by 602.5% to -$12.6 million in 2025.
  • Business Quant data shows Enterprise Value for TIVC at -$12.6 million in Q4 2025, -$3.5 million in Q3 2025, and -$975000.0 in Q2 2025.